Creation of a long-acting nanoformulated dolutegravir

Potent antiretroviral activities and a barrier to viral resistance characterize the human immunodeficiency virus type one (HIV-1) integrase strand transfer inhibitor dolutegravir (DTG). Herein, a long-acting parenteral DTG was created through chemical modification to improve treatment outcomes. A hy...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Nat Commun
Autores principales: Sillman, Brady, Bade, Aditya N., Dash, Prasanta K., Bhargavan, Biju, Kocher, Ted, Mathews, Saumi, Su, Hang, Kanmogne, Georgette D., Poluektova, Larisa Y., Gorantla, Santhi, McMillan, JoEllyn, Gautam, Nagsen, Alnouti, Yazen, Edagwa, Benson, Gendelman, Howard E.
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5799307/
https://ncbi.nlm.nih.gov/pubmed/29402886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-018-02885-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares